Skip to main content

Select Drug Profiles

Select Drug Profiles

Tavalisse (Fostamatinib Disodium Hexahydrate) First Spleen Tyrosine Kinase Inhibitor Approved for Chronic Immune Thrombocytopenia

FDA Approvals, In the News, Select Drug Profiles

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

FDA Approvals, In the News, Select Drug Profiles

Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer

Select Drug Profiles

Eylea (Aflibercept), a VEGF Receptor Inhibitor, Receives New Indication for All Stages of Diabetic Retinopathy

Lilly Ostrovsky

Lilly Ostrovsky

Select Drug Profiles

Imbruvica (Ibrutinib) plus Gazyva (Obinutuzumab) First Chemotherapy-Free Combination Approved as First-Line Treatment for Patients with CLL or SLL

Lilly Ostrovsky

Lilly Ostrovsky

Select Drug Profiles

Mavenclad (Cladribine) First Short-Course Oral Therapy Approved for Relapsing-Remitting Multiple Sclerosis and Active Secondary Progressive Disease

Lilly Ostrovsky

Lilly Ostrovsky

Select Drug Profiles

Skyrizi (Risankizumab-rzaa) a New Treatment Option Approved by the FDA for Patients with Moderate-to-Severe Plaque Psoriasis

Loretta Fala

Select Drug Profiles

Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations

Loretta Fala

Select Drug Profiles

Spravato (Esketamine) Nasal Spray First NMDA Receptor Antagonist Approved by the FDA for Adults with Treatment-Resistant Depression

Loretta Fala

Select Drug Profiles

Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura

Loretta Fala

12
13
14
15
16
17
18

Page 15 of 20
Results 141 - 150 of 200